Novel advances in pancreatic cancer treatment (Q28282794)

Expert Review of Anticancer Therapy

Europe PubMed Central

title

Novel advances in pancreatic cancer treatment (English)

0 references

1 reference

Michel Vulfovich

1

0 references

Caio Rocha-Lima

series ordinal

2

0 references

language of work or name

English

0 references

publication date

June 2008

0 references

published in

0 references

volume

8

0 references

issue

6

0 references

page(s)

993-1002

0 references

cites work

Chemotherapy for pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

A decade of tyrosine kinases: from gene discovery to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Src family kinases in tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Kinase inhibitors and cytotoxic drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993

Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.6.993